India

AAP Leader Saurabh Bharadwaj Questions Centre On Allowing Covishield Vaccine In India Despite Ban

After the worldwide withdrawal of the AstraZeneca COVID-19 vaccine, Aam Aadmi Party leader Saurabh Bharadwaj raised questions on Wednesday regarding the Indian government’s decision to allow the Covishield vaccine, especially in light of most European countries banning it due to side effects.

In a statement posted on X, Saurabh remarked, “When most European Nations had banned the use of Covishield vaccine due to side effects in March 2021, Indian Govt continued the use of this vaccine. Now facing heat from Courts in the UK, they have withdrawn the vaccine world over.”

AstraZeneca withdrew its vaccine after it acknowledged, for the first time in court documents, that it can cause a rare and dangerous side effect, as reported by The Telegraph, a British newspaper.

AstraZeneca stated that the vaccine was being removed from markets for commercial reasons, clarifying that it was no longer being produced or supplied due to updated vaccines combating new variants.

The withdrawal application was filed on March 5 and took effect on May 7. Following the company’s decision to withdraw its “marketing authorisation,” the vaccine can no longer be used in the European Union.

Similar applications will be filed in the UK and other countries in the coming months that have approved the vaccine, known as Vaxzevria.

In recent months, Vaxzevria has faced scrutiny over a very rare side effect causing blood clots and low blood platelet counts. AstraZeneca admitted in court documents filed in the High Court in February that the vaccine “can, in very rare cases, cause TTS.”

AstraZeneca maintained that the decision to withdraw the vaccine was unrelated to the case or the admission of its potential to cause TTS, labeling the timing as a mere coincidence, according to The Telegraph.

Last week, AstraZeneca reaffirmed its commitment to patient safety while emphasizing the overall safety profile of the vaccine.

Despite these rare incidents, the pharmaceutical company reiterated that extensive clinical trial data and real-world evidence consistently support the safety and efficacy of the vaccine. Regulatory agencies worldwide continue to assert that the benefits of vaccination outweigh the risks of such extremely rare side effects.

Nisha Srivastava

Nisha Srivastava is an influential blog writer and content editor associated with The Daily Guardian, with over 10 years of experience in writing.

Recent Posts

India in intelligent era, tech-driven governance

BJP formed a third successive government under the leadership of Prime Minister Narendra Modi. Since…

25 minutes ago

Ceasefire in Gaza: A temporary respite or a prelude to future conflict?

The announcement of a ceasefire deal in conflict between Hamas and Israel This agreement marks…

28 minutes ago

Pope Francis Suffers Arm Injury After Second Fall in a Month

Pope Francis injured his arm after suffering his second fall within a month. The incident…

32 minutes ago

Brazil Former President Bolsonaro Denied Passport Return Ahead Of Trump’s Inauguration

Jair Bolsonaro’s passport remains seized as he faces coup-related charges. His attempt to attend Trump’s…

43 minutes ago

Russian Diplomats Sneaks Into UK Parliament’s Restricted Area, Sparking National Security Alarm

A group of Russian diplomats infiltrated a private section of UK Parliament during a tour,…

57 minutes ago

Gukesh Became Second Chess Player after Viswanathan Anand to Receive Khel Ratna

World Chess Champion Gukesh thanked the nation after being conferred with the Khel Ratna award,…

1 hour ago